The aim of this study was to evaluate umami-related components and their evolution in Canadian pork destined for the Japanese market. Export quality pork loins for Japan were subjectively selected on-line for marbling, colour and firmness; remaining loins were retained for the domestic market. At 48h post-mortem, samples were aged 5d at 4.0°C (fresh) or 13, 28, 43 or 58d at -1.7°C (chilled). Meat qualities differed only in pH (<0.1 pH unit; P<0.05). Generally, free amino acid concentrations increased and nucleotide concentrations decreased with longer ageing periods. The equivalent umami concentration (EUC) was highest in the pork aged 5d at 4.0°C and at 43d -1.7°C (P<0.05) which is estimated as the transportation time for Canadian chilled exports to Japan. A lack of differences in EUC between domestic and export pork and between fresh and 43d chilled ageing demonstrates that Canadian chilled pork in Japan has the EUC of its fresh 5d counterpart.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.meatsci.2016.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global expansion of microphysiological systems (MPS) and Japan's initiatives: Innovation in pharmaceutical development and path to regulatory acceptance.
Drug Metab Pharmacokinet
December 2024
Division of Pharmacology, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan; Sojo University, Graduate School of Engineering, Department of Life Science, 4-22-1 Ikeda, Nishi-ku, Kumamoto City, Kumamoto, 816-0082, Japan. Electronic address:
Microphysiological systems (MPS) are gaining global attention as potential game-changers in pharmaceutical development. Since 2013, MPS suppliers from university laboratories in the United States and Europe have competed to develop these devices. After the development phase, the focus shifted to the accumulation of applications using MPS for pharmaceutical companies and end users.
View Article and Find Full Text PDFFinal Analysis of Post-Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan.
Cancer Med
January 2025
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Introduction: Avelumab, an anti-programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese patients, post-marketing surveillance (PMS) was required to evaluate outcomes (safety and effectiveness) in patients with RCC who received avelumab + axitinib treatment in clinical practice in Japan.
Materials And Methods: We report data from prospective, noncomparative, multicenter, observational PMS in patients with RCC who received ≥ 1 dose of avelumab.
Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
Obes Res Clin Pract
January 2025
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. Electronic address:
Objective: To explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.
Methods: In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.
Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data.
BMC Geriatr
January 2025
Department of Pharmacy, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi Nishitokyo-Shi, Tokyo, 202-8585, Japan.
Background: Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of edaravone use with ADL using real-world data of older patients with atherothrombotic stroke.
Methods: This retrospective observational research using the Medical Data Vision database in Japan included patients aged 65 years and older who had acute ischemic stroke of the atherothrombotic subtype.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!